NFKB1 and diffuse large B-cell lymphoma: In addition, CQ/HCQ treatment also prevented IκBα degradation, consistent with a previous report showing that the inhibition of autophagy by CQ blocks bortezomib-induced NF-κB activation in diffuse large B-cell lymphoma (DLBCL) cells [31].